TOP TEN perturbations for P59533 (Homo sapiens)

Organism: Homo sapiens
Gene: P59533
Selected probe(set): 1553555_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of P59533 (1553555_at) across 5339 perturbations tested by GENEVESTIGATOR:

medulloblastoma study 2 / non-tumor brain tissue

Relative Expression (log2-ratio):1.31143
Number of Samples:4 / 9
Experimental medulloblastoma study 2
Primary tumor tissue sample from the infratentorial brain of pediatric patients with large-cell anaplastic medulloblastoma.
Control non-tumor brain tissue
Histologically normal brain tissue at rapid autopsy from patients who died from atypical teratoid/rhabdoid tumor.

small cell lung cancer study 4 (XCL from CDX) / small cell lung cancer study 4 (cell line)

Relative Expression (log2-ratio):-1.210679
Number of Samples:11 / 4
Experimental small cell lung cancer study 4 (XCL from CDX)
Xenograft-derived cell lines (XCL) established from a small cell lung carcinoma (SCLC) publicly available cell lines derived xenografts (CDX derived cell lines). Xenografts were grown in the flanks of a nude mice. Obtained cells were cultivated under conventional tissue culture conditions.
Control small cell lung cancer study 4 (cell line)
Various small cell lung cancer (SCLC) publicly available cell lines samples.

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)

Relative Expression (log2-ratio):-1.1007605
Number of Samples:5 / 17
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they died from unknown reasons.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; dead)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they died from unknown reasons.

Xq12?q13.3 duplication syndrome study 1 / normal lymphoblastoid cell line sample

Relative Expression (log2-ratio):1.0427284
Number of Samples:2 / 13
Experimental Xq12?q13.3 duplication syndrome study 1
Lymphoblastoid cell line samples from two brothers with Xq12?q13.3 duplication. The patients are affected by severe autism and global developmental delay with multiorgan involvement.
Control normal lymphoblastoid cell line sample
Lymphoblastoid cell line samples from healthy subjects.

DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive) / DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)

Relative Expression (log2-ratio):-1.0005293
Number of Samples:28 / 14
Experimental DLBCL study 4 (unclassified DLBCL; baseline; RCHOP; alive)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, prednisone with monoclonal antibody rituximab (RCHOP) and during follow up period they were alive.
Control DLBCL study 4 (unclassified DLBCL; baseline; CHOP; alive)
Tumor lymph node biopsy samples of patients with unclassified diffuse large B-cell lymphoma (DLBCL) collected before any treatment. Later patients received chemotherapy composed of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) and during follow up period they were alive.

engineered skin substitute study 2 (late) / engineered skin substitute study 1 (late)

Relative Expression (log2-ratio):0.9858351
Number of Samples:5 / 3
Experimental engineered skin substitute study 2 (late)
Human skin substitutes tissue samples collected after 42 and 56 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (late)
Human skin substitutes tissue samples collected after 14 days in culture.

stem cell differentiation study 41 (hES-T3 EB) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):-0.9566126
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

engineered skin substitute study 2 (intermediate) / engineered skin substitute study 1 (intermediate)

Relative Expression (log2-ratio):0.9389105
Number of Samples:6 / 3
Experimental engineered skin substitute study 2 (intermediate)
Human skin substitutes tissue samples collected after 14 and 28 days after transplantation to athymic mice.
Control engineered skin substitute study 1 (intermediate)
Human skin substitutes tissue samples collected after 7 days in culture.

tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample

Relative Expression (log2-ratio):-0.92957115
Number of Samples:3 / 3
Experimental tunicamycin study 2 (2ug/ml; HCT 116 DICER1(-/-))
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 2 ug/ml tunicamycin for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:---
Control untreated HCT 116 DICER1(-/-) cell sample
Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS.

glioma study 17 (small cell glioblastoma; A2B5+) / non-tumor oligodendrocyte progenitor cell sample (cortex)

Relative Expression (log2-ratio):-0.9279909
Number of Samples:2 / 3
Experimental glioma study 17 (small cell glioblastoma; A2B5+)
Oligodendrocyte progenitor cells (OPC) isolated from high grade small cell glioblastoma (grade IV). OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen. Patients were 56 ? 3 years old males.
Control non-tumor oligodendrocyte progenitor cell sample (cortex)
Oligodendrocyte progenitor cells (OPC) isolated from cortical tissue, which was obtained from patients with epilepsy, but without any manifested brain cancer. OPC were isolated using magnetic-activated cell sorting (MACS) with antibodies against A2B5 antigen.